(2S)-3-dibenzofuran-3-yl-2-(diphenoxyphosphorylmethylamino)propanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (2S)-3-dibenzofuran-3-yl-2-(diphenoxyphosphorylmethylamino)propanoic acid
• 化学式: C₂₈H₂₄NO₆P
• 分子量: 501.5
• InChiKey: LKDBINXYOPVFRR-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
  申请人：Amberg Wilhelm

  公开号：US20090311266A1

  公开（公告）日：2009-12-17

  The invention relates to the use of an endothelin blocker in combination with an α v β 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an α v β 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

  本发明涉及将内皮素阻滞剂与αvβ3整合素受体拮抗剂结合使用以治疗或预防疾病，特别是涉及使用一种制药组合物，包括内皮素阻塞剂和αvβ3整合素受体拮抗剂，用于治疗或预防心血管疾病，特别是用于治疗或预防血管损伤或再血管化治疗后的再狭窄，以及该制药组合物本身。
• INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1227847A2

  公开（公告）日：2002-08-07
• [EN] INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND alpha V beta 3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY<br/>[FR] INHIBITEURS DE VOIE DE SIGNALISATION DE L'ENDOTHELINE ET ANTAGONISTES DE RECEPTEURS DE L'INTEGRINE POUR TRAITEMENT COMBINE
  申请人：BASF AG

  公开号：WO2001024827A2

  公开（公告）日：2001-04-12

  The invention relates to the use of an endothelin blocker in combination with an αvβ3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an αvβ3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.